Background/Aims: Piceatannol, an analog and metabolite of resveratrol, is effective against various disorders including malignancy. It is in part effective by triggering suicidal death or apoptosis of tumor cells. Cellular mechanisms mediating the proapoptotic effect of Piceatannol include mitochondrial depolarization and cytochrome c release. Erythrocytes lack mitochondria but may nevertheless enter suicidal death or eryptosis, which is characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Cellular mechanisms involved in the triggering of eryptosis include increase of cytosolic Ca2+ activity ([Ca2+]i), oxidative stress and ceramide formation. The present study explored, whether Piceatannol induces eryptosis and, if so, to shed some light on the cellular mechanisms involved. Methods: Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, reactive oxygen species (ROS) formation from 2',7'-dichlorodihydrofluorescein (DCF) diacetate-dependent fluorescence, and ceramide abundance utilizing specific antibodies. Hemoglobin concentration in the supernatant was taken as measure of hemolysis. Results: A 48 hours exposure of human erythrocytes to Piceatannol (10 - 20 µM) significantly increased the percentage of annexin-V-binding cells, significantly decreased forward scatter, significantly increased DCFDA-fluorescence, significantly increased ceramide abundance, but did not significantly increase Fluo3-fluorescence. Removal of extracellular Ca2+ slightly blunted but did not abolish the effect of Piceatannol on annexin-V-binding and forward scatter. Piceatannol (20 µM) significantly augmented the increase of annexin-V-binding, but significantly blunted the decrease of forward scatter following treatment with the Ca2+ ionophore ionomycin. Conclusions: Piceatannol triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect at least in part downstream of Ca2+ and involving oxidative stress and ceramide formation.

Piceatannol (3,3′,4,5′-tetrahydroxy-trans-stilbene), a naturally occurring hydroxylated analogue of resveratrol found in diverse plants including grapes and passion fruit [1,2,3], is effective against diverse disorders including hypercholesterolemia, arrhythmia, atherosclerosis and malignancy [1,2,3]. Piceatannol fosters vasodilation, counteracts angiogenesis as well as oxidative stress [2] and displays anti-inflammatory as well as antimicrobial activities [1]. Cellular mechanisms triggered by piceatannol include inhibition of cyclooxygenase activity [2], cell-cycle arrest [1]; upregulation of Bid, Bax, Bik, Bok, Fas as well as P21(WAF1) [1], down-regulation of Bcl-xL as well as BCL-2 [1], mitochondrial depolarization [1], cytochrome c release [1], and caspase activation [1]. Piceatannol modifies gene expression by downregulation of transcription factor NF-kB [1] and Janus kinase JAK1 [1]. Depending on the cell type piceatannol may either stimulate [1,4] or inhibit [1] apoptosis.

In analogy to apoptosis of nucleated cells erythrocytes may enter eryptosis [5], the suicidal erythrocyte death characterized by cell shrinkage [6] and cell membrane scrambling with phosphatidylserine translocation to the cell surface [5]. Stimulators of eryptosis include increase of cytosolic Ca2+ activity ([Ca2+]i) [5], ceramide [7], oxidative stress [5], energy depletion [5], activated caspases [5,8,9], stimulated activity of casein kinase 1á, Janus-activated kinase JAK3, protein kinase C, and p38 kinase [5], as well as impaired activity of AMP activated kinase AMPK, cGMP-dependent protein kinase, and sorafenib/sunitinib sensitive kinases [5]. Eryptosis could be stimulated by a wide variety of xenobiotics [5,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51].

In order to test whether eryptosis could be modified by Piceatannol, human erythrocytes drawn from healthy volunteers were exposed to Piceatannol and phosphatidylserine surface abundance, cell volume, [Ca2+]i, ROS formation, and ceramide abundance determined by flow cytometry.

Erythrocytes, solutions and chemicals

Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl2,at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to Piceatannol (MedChem Express, Princeton, USA). In order to estimate the impact of Piceatannol on eryptosis due to high [Ca2+]i, erythrocytes were exposed for 30 min to a combination of Piceatannol and the Ca2+ ionophore ionomycin (Merck Millipore, Darmstadt, Germany).

FACS Analysis of Annexin-V-binding and forward scatter

After incubation under the respective experimental condition, a 100 µl cell suspension was washed in Ringer solution containing 5 mM CaCl2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 20 min under protection from light. The annexin-V-abundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, Germany). Annexin-V-binding was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding cells and control cells. The same threshold was used for untreated and Piceatannol treated erythrocytes.

Measurement of Intracellular Ca2+

After incubation, erythrocytes were washed in Ringer solution and loaded with Fluo-3/AM (Biotium, Hayward, USA) in Ringer solution containing 5 µM Fluo-3/AM. The cells were incubated at 37°C for 30 min. Ca2+-dependent fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur.

Quantification of Reactive oxidant species (ROS)

Oxidative stress was determined utilizing 2',7'-dichlorodihydrofluorescein (DCF) diacetate. After incubation, a 100 µl suspension of erythrocytes was washed in Ringer solution and stained with DCF diacetate (Sigma, Schnelldorf, Germany) in Ringer solution containing DCFDA at a final concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and washed two times in Ringer solution. The DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD).

Determination of Ceramide formation

To determine ceramide abundance, a monoclonal antibody-based assay was used. To this end, cells were stained for 1 hour at 37°C with 1 µg/ml anti ceramide antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum albumin (BSA) at a dilution of 1:10. The samples were washed twice with PBS-BSA. The cells were stained for 30 minutes with polyclonal fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples were analyzed by flow cytometric analysis with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. As a control, secondary antibody alone was used.

Hemolysis

For the determination of hemolysis, the samples were centrifuged (10 min at 2000 rpm, room temperature) after incubation, and the supernatants were harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration of the supernatant was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.

Statistics

Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.

The present study explored whether Piceatannol stimulates eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and phospholipid scrambling of the cell membrane with phosphatidylserine translocation to the cell surface.

Erythrocyte volume was estimated from forward scatter which was determined utilizing flow cytometry. The measurements were performed after incubation of the erythrocytes 48 hours in Ringer solution without or with Piceatannol (5 - 20 µM). As shown in Fig. 1A, B, Piceatannol slightly decreased the average erythrocyte forward scatter, an effect reaching statistical significance at 20 µM Piceatannol. Fig. 1C, D demonstrates that Piceatannol significantly increased the percentage of both severely swollen and severely shrunken erythrocytes.

Fig. 1

Effect of Piceatannol on erythrocyte forward scatter. A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of the erythrocyte forward scatter (FSC) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). C. Arithmetic means ± SEM (n = 10) of the percentage erythrocytes with forward scatter (FSC) <200 following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). D. Arithmetic means ± SEM (n = 10) of the percentage erythrocytes with forward scatter (FSC) >800 following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). **(p<0.01), ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Fig. 1

Effect of Piceatannol on erythrocyte forward scatter. A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of the erythrocyte forward scatter (FSC) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). C. Arithmetic means ± SEM (n = 10) of the percentage erythrocytes with forward scatter (FSC) <200 following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). D. Arithmetic means ± SEM (n = 10) of the percentage erythrocytes with forward scatter (FSC) >800 following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). **(p<0.01), ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Close modal

Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding, as determined by flow cytometry. Prior to measurements, the erythrocytes were again incubated for 48 hours in Ringer solution without or with Piceatannol (5 - 20 µM). As shown in Fig. 2, a 48 hours exposure to Piceatannol increased the percentage of phosphatidylserine exposing erythrocytes, an effect reaching statistical significance at 10 µM Piceatannol. For comparison, the percentage of hemolysis after 48 hours exposure in Ringer solution without or with Piceatannol (5 - 20 µM) is shown in the same bar chart (Fig. 2B; grey bars).

Fig. 2

Effect of Piceatannol on phosphatidylserine exposure and hemolysis. A. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). For comparison, arithmetic means ± SEM (n = 10) of the percentage of hemolysis is shown as grey bars. ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Fig. 2

Effect of Piceatannol on phosphatidylserine exposure and hemolysis. A. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5 - 20 µM). For comparison, arithmetic means ± SEM (n = 10) of the percentage of hemolysis is shown as grey bars. ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Close modal

Fluo3-fluorescence was taken as a measure of cytosolic Ca2+ activity ([Ca2+]i). As a result, the average Fluo3-fluorescence was similar following a 48 hours incubation without Piceatannol as in the presence of Piceatannol (5 - 20 µM) (Table 1).

Table 1

Fluo3-fluorescence following incubation for 48 hours without or with Piceatannol treatment

Fluo3-fluorescence following incubation for 48 hours without or with Piceatannol treatment
Fluo3-fluorescence following incubation for 48 hours without or with Piceatannol treatment

A next series of experiments explored whether the Piceatannol-induced translocation of phosphatidylserine or erythrocyte shrinkage required entry of extracellular Ca2+. To this end, erythrocytes were incubated for 48 hours in the absence or presence of 20 µM Piceatannol in the presence or nominal absence of extracellular Ca2+. As illustrated in Fig. 3, removal of extracellular Ca2+ slightly, but significantly blunted the effect of Piceatannol on forward scatter. However, even in the absence of extracellular Ca2+, Piceatannol significantly decreased the erythrocyte forward scatter. Similar observations were made with annexin-V-binding. Removal of extracellular Ca2+ slightly, but significantly blunted the effect of Piceatannol on annexin-V-binding. However, even in the absence of extracellular Ca2+, Piceatannol significantly increased the percentage of annexin-V-binding erythrocytes (Fig. 3). Thus, Piceatannol-induced cell membrane scrambling was in large part triggered by mechanisms insensitive to entry of extracellular Ca2+.

Fig. 3

Ca2+ sensitivity of Piceatannol -induced erythrocyte shrinkage and phosphatidylserine exposure. A,B. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) Piceatannol (20 µM) in the presence (A) and absence (B) of extracellular Ca2+. C. Arithmetic means ± SEM (n = 10) of forward scatter of erythrocytes after a 48 hours treatment with Ringer solution without (white bars) or with (black bars) Piceatannol (20 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. D,E. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) Piceatannol (20 µM) in the presence (D) and absence (F) of extracellular Ca2+. F. Arithmetic means ± SEM (n = 10) of annexin-V-binding of erythrocytes after a 48 hours treatment with Ringer solution without (white bars) or with (black bars) Piceatannol (20 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. *(p<0.05),***(p<0.001) indicates significant difference from the absence of Piceatannol, #(p<0.05), ##(p<0.01) indicates significant difference from the nominal absence of Ca2+ (ANOVA).

Fig. 3

Ca2+ sensitivity of Piceatannol -induced erythrocyte shrinkage and phosphatidylserine exposure. A,B. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) Piceatannol (20 µM) in the presence (A) and absence (B) of extracellular Ca2+. C. Arithmetic means ± SEM (n = 10) of forward scatter of erythrocytes after a 48 hours treatment with Ringer solution without (white bars) or with (black bars) Piceatannol (20 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. D,E. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) Piceatannol (20 µM) in the presence (D) and absence (F) of extracellular Ca2+. F. Arithmetic means ± SEM (n = 10) of annexin-V-binding of erythrocytes after a 48 hours treatment with Ringer solution without (white bars) or with (black bars) Piceatannol (20 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. *(p<0.05),***(p<0.001) indicates significant difference from the absence of Piceatannol, #(p<0.05), ##(p<0.01) indicates significant difference from the nominal absence of Ca2+ (ANOVA).

Close modal

A next series of experiments explored whether Piceatannol modified cell shrinkage and translocation of phosphatidylserine following increase of cytosolic Ca2+ activity by treatment of the erythrocytes with Ca2+ ionophore ionomycin (1 µM). To this end, erythrocytes were incubated for 48 hours in the absence or presence of 20 µM Piceatannol and subsequently treated for 30 minutes with ionomycin (1 µM). As illustrated in Fig. 4A following Piceatannol pretreatment, ionomycin increased cytosolic Ca2+ activity to similar values in erythrocytes with or without Piceatannol treatment. However, the effect of ionomycin on forward scatter was significantly blunted (Fig. 4C) and the effect of ionomycin on annexin-V-binding significantly stronger following Piceatannol pretreatment (Fig. 4B).

Fig. 4

Effect of Ca2+ ionophore ionomycin on phosphatidylserine exposure in the presence and absence of Piceatannol. A-C. Arithmetic means ± SEM (n = 10) of (A) the Fluo3-fluorescence, (B) the percentage of annexin-V-binding erythrocytes, and (C) the forward scatter following incubation for 30 min in the absence (left bars, -ionomycin) or presence (right bars, +ionomycin) of Ca2+ ionophore ionomycin (1 µM) after a 48 hours preincubation in the absence (white bars) or presence (black bars) of 20 µM Piceatannol. *(p<0.05), ***(p<0.001) indicates significant difference from the absence of Piceatannol. ###(p<0.001) indicates significant difference from the absence of ionomycin (ANOVA).

Fig. 4

Effect of Ca2+ ionophore ionomycin on phosphatidylserine exposure in the presence and absence of Piceatannol. A-C. Arithmetic means ± SEM (n = 10) of (A) the Fluo3-fluorescence, (B) the percentage of annexin-V-binding erythrocytes, and (C) the forward scatter following incubation for 30 min in the absence (left bars, -ionomycin) or presence (right bars, +ionomycin) of Ca2+ ionophore ionomycin (1 µM) after a 48 hours preincubation in the absence (white bars) or presence (black bars) of 20 µM Piceatannol. *(p<0.05), ***(p<0.001) indicates significant difference from the absence of Piceatannol. ###(p<0.001) indicates significant difference from the absence of ionomycin (ANOVA).

Close modal

Eryptosis is further stimulated by oxidative stress. Reactive oxygen species (ROS) was thus quantified utilizing 2′,7′-dichlorodihydrofluorescein (DCF) diacetate. As indicated in Fig. 5, the DCFDA-fluorescence was higher following exposure to Piceatannol than in the absence of Piceatannol, a difference reaching statistical significance at 10 µM Piceatannol concentration.

Fig. 5

Effect of Piceatannol on erythrocyte ROS formation. A. Original histogram of DCFDA-fluorescence in erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of Piceatannol (20 µM). B. Arithmetic means ± SEM (n = 10) of the DCFDA-fluorescence (arbitrary units) in erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5- 20 µM). *(p<0.05), ***(p<0.001) indicate significant difference from the absence of Piceatannol (ANOVA).

Fig. 5

Effect of Piceatannol on erythrocyte ROS formation. A. Original histogram of DCFDA-fluorescence in erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of Piceatannol (20 µM). B. Arithmetic means ± SEM (n = 10) of the DCFDA-fluorescence (arbitrary units) in erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with (black bars) Piceatannol (5- 20 µM). *(p<0.05), ***(p<0.001) indicate significant difference from the absence of Piceatannol (ANOVA).

Close modal

A further stimulator of eryptosis is ceramide. Ceramide abundance at the erythrocyte surface was thus quantified utilizing specific antibodies. As shown in Fig. 6, the ceramide abundance was significantly higher following exposure to 20 µM Piceatannol than in the absence of Piceatannol.

Fig. 6

Effect of Piceatannol on ceramide abundance at the erythrocyte surface. A. Original histogram of ceramide abundance in erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of the ceramide abundance (arbitrary units) in erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with (black bar) presence of 20 µM Piceatannol. ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Fig. 6

Effect of Piceatannol on ceramide abundance at the erythrocyte surface. A. Original histogram of ceramide abundance in erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black line) presence of 20 µM Piceatannol. B. Arithmetic means ± SEM (n = 10) of the ceramide abundance (arbitrary units) in erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with (black bar) presence of 20 µM Piceatannol. ***(p<0.001) indicates significant difference from the absence of Piceatannol (ANOVA).

Close modal

The present observations reveal that exposure of human erythrocytes drawn from healthy individuals to the 3,3′,4,5′-tetrahydroxy-trans-stilbene (Piceatannol) is followed by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Thus, Piceatannol stimulates the suicidal erythrocyte death or eryptosis.

The experiments further shed some light on the cellular mechanisms involved. Piceatannol did not appreciably increase cytosolic Ca2+ activity ([Ca2+]i). Instead, it slightly tended to decrease Fluo-3AM fluorescence, an effect, however, not reaching statistical significance. We cannot rule out an artifact, such as cellular loss of fluorescent dye. Nevertheless, the effect of Piceatannol on cell membrane scrambling was slightly, but significantly blunted following removal of extracellular Ca2+. However, Piceatannol increased the percentage of annexin-V-binding erythrocytes even in the absence of extracellular Ca2+. Moreover, Piceatannol augmented cell membrane scrambling in erythrocytes loaded with Ca2+ by treatment with the Ca2+ ionophore ionomycin. Thus, Piceatannol apparently sensitized the cells to the scrambling effect of Ca2+ and was effective downstream of Ca2+. The sensitivity of cell membrane scrambling to Ca2+ could be enhanced by ceramide [5]. Piceatannol indeed enhanced the ceramide abundance, which could well contribute to or even account for the sensitization of cell membrane scrambling to [Ca2+]i. Moreover, the stimulation of cell membrane scrambling by Piceatannol was paralleled by oxidative stress, a major stimulator of eryptosis [5].

The effect of Piceatannol on cell shrinkage was again slightly, but significantly blunted by removal of Ca2+ from the extracellular space. On the other hand, Piceatannol significantly blunted the effect of the Ca2+ ionophore ionomycin on cell shrinkage. Ionomycin triggers cell shrinkage by increase of [Ca2+]i with subsequent activation of Ca2+ sensitive K+ channels, K+ exit, cell membrane hyperpolarization, Cl- exit and thus cellular loss of KCl with water. Possibly, preincubation to Piceatannol was followed by impairment of Na+/K+ ATPase with gain of cytosolic Na+ and loss of cellular K+. As a result, the K+ exit, hyperpolarisation and Cl- loss following opening of Ca2+ sensitive K+ channels would be blunted by prior treatment with Piceatannol.

At low concentrations Piceatannol decreases and at high concentrations Piceatannol increases hemolysis and thus release of hemoglobin. Hemoglobin released into circulating blood may pass the renal glomerular filter, precipitate in the acidic lumen of renal tubules, occlude nephrons and thus lead to renal failure [52]. An important function of eryptosis is the disposal of defective erythrocytes prior to hemolysis. Eryptosis further accomplishes elimination of erythrocytes infected with the malaria pathogen Plasmodium [5].

Excessive eryptosis may, however, result in anemia, if the loss of eryptotic erythrocytes outcasts the formation of new erythrocytes by erythropoiesis [5]. Phosphatidylserine exposing erythrocytes further adhere to the vascular wall [53], stimulate blood clotting and trigger thrombosis [54,55,56], thus impairing microcirculation [7,54,57,58,59,60]. Enhanced eryptosis may thus contribute to the anemia and/or deranged microcirculation in several clinical conditions, such as chronic dehydration [61], hyperphosphatemia [62], chronic kidney disease (CKD) [63,64,65,66], hemolytic-uremic syndrome [67], diabetes [68], hepatic failure [69], malignancy [5], sepsis [70], sickle-cell disease [5], beta-thalassemia [5], Hb-C and G6PD-deficiency [5], as well as Wilsons disease [71]. At least in theory, treatment of affected patients with Piceatannol may further aggravate anemia.

The effect of Piceatannol contrasts that of the related substance resveratrol [72,73,74], which has been shown to inhibit eryptosis [75].

In conclusion, Piceatannol triggers eryptosis with cell shrinkage and cell membrane scrambling, an effect apparently independent from Ca2+ entry, but involving oxidative stress and ceramide.

The authors acknowledge the meticulous preparation of the manuscript by Tanja Loch. The study was supported by the Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University.

The authors of this manuscript state that they have no conflicts of interest to declare.

1.
Piotrowska H, Kucinska M, Murias M: Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res 2012;750:60-82.
2.
Seyed MA, Jantan I, Bukhari SN, Vijayaraghavan K: A Comprehensive Review on the Chemotherapeutic Potential of Piceatannol for Cancer Treatment, with Mechanistic Insights. J Agric Food Chem 2016;64:725-737.
3.
Tang YL, Chan SW: A review of the pharmacological effects of piceatannol on cardiovascular diseases. Phytother Res 2014;28:1581-1588.
4.
Jancinova V, Perecko T, Nosal R, Svitekova K, Drabikova K: The natural stilbenoid piceatannol decreases activity and accelerates apoptosis of human neutrophils: involvement of protein kinase C. Oxid Med Cell Longev 2013;2013:136539.
5.
Lang E, Lang F: Mechanisms and pathophysiological significance of eryptosis, the suicidal erythrocyte death. Semin Cell Dev Biol 2015;39:35-42.
6.
Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM: Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560.
7.
Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F: Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012;303:C991-999.
8.
Lau I P, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012;6:847-856.
9.
Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013;50:489-495.
10.
Alzoubi K, Calabròa S, Bissinger R, Abed M, Faggio C, Lang F: Stimulation of Suicidal Erythrocyte Death by Artesunate. Cell Physiol Biochem 2014;34:2232-2244.
11.
Alzoubi K, Egler J, Abed M, Lang F: Enhanced Eryptosis Following Auranofin Exposure. Cell Physiol Biochem 2015;37:1018-1028.
12.
Arnold M, Bissinger R, Lang F: Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014;34:1756-1767.
13.
Arnold M, Lang E, Modicano P, Bissinger R, Faggio C, Abed M, Lang F: Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014;114:421-426.
14.
Bissinger R, Barking S, Alzoubi K, Liu G, Liu G, Lang F: Stimulation of Suicidal Erythrocyte Death by the Antimalarial Drug Mefloquine. Cell Physiol Biochem 2015;36:1395-1405.
15.
Bissinger R, Bouguerra G, Stockinger K, Abbes S, Lang F: Triggering of Suicidal Erythrocyte Death by Topotecan. Cell Physiol Biochem 2015;37:1607-1618.
16.
Bissinger R, Fischer S, Jilani K, Lang F: Stimulation of Erythrocyte Death by Phloretin. Cell Physiol Biochem 2014;34:2256-2265.
17.
Bissinger R, Lupescu A, Zelenak C, Jilani K, Lang F: Stimulation of eryptosis by cryptotanshinone. Cell Physiol Biochem 2014;34:432-442.
18.
Bouguerra G, Aljanadi O, Bissinger R, Abbes S, Lang F: Embelin-Induced Phosphatidylserine Translocation in the Erythrocyte Cell Membrane. Cell Physiol Biochem 2015;37:1629-1640.
19.
Bouguerra G, Bissinger R, Abbes S, Lang F: Stimulation of Eryptosis by Narasin. Cell Physiol Biochem 2015;37:1807-1816.
20.
Bouguerra G, Bissinger R, Abbes S, Lang F: Zopolrestat Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:1537-1546.
21.
Briglia M, Fazio A, Faggio C, Laufer S, Alzoubi K, Lang F: Triggering of Suicidal Erythrocyte Death by Ruxolitinib. Cell Physiol Biochem 2015;37:768-778.
22.
Briglia M, Fazio A, Signoretto E, Faggio C, Lang F: Edelfosine Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2221-2230.
23.
Calabro S, Alzoubi K, Faggio C, Laufer S, Lang F: Triggering of Suicidal Erythrocyte Death Following Boswellic Acid Exposure. Cell Physiol Biochem 2015;37:131-142.
24.
Egler J, Lang F: Licochalcone A Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2060-2070.
25.
Faggio C, Alzoubi K, Calabro S, Lang F: Stimulation of suicidal erythrocyte death by PRIMA-1. Cell Physiol Biochem 2015;35:529-540.
26.
Fazio A, Briglia M, Faggio C, Alzoubi K, Lang F: Stimulation of Suicidal Erythrocyte Death by Garcinol. Cell Physiol Biochem 2015;37:805-815.
27.
Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F: Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014;33:1516-1526.
28.
Lang E, Jilani K, Bissinger R, Rexhepaj R, Zelenak C, Lupescu A, Lang F, Qadri SM: Vitamin D-Rich Diet in Mice Modulates Erythrocyte Survival. Kidney Blood Press Res 2015;40:403-412.
29.
Lang E, Zelenak C, Eberhard M, Bissinger R, Rotte A, Ghashghaeinia M, Lupescu A, Lang F, Qadri SM: Impact of Cyclin-Dependent Kinase CDK4 Inhibition on Eryptosis. Cell Physiol Biochem 2015;37:1178-1186.
30.
Lupescu A, Bissinger R, Goebel T, Salker MS, Alzoubi K, Liu G, Chirigiu L, Mack AF, Qadri SM, Lang F: Enhanced suicidal erythrocyte death contributing to anemia in the elderly. Cell Physiol Biochem 2015;36:773-783.
31.
Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F: Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014;33:670-680.
32.
Lupescu A, Bissinger R, Warsi J, Jilani K, Lang F: Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem 2014;33:1838-1848.
33.
Malik A, Bissinger R, Calabro S, Faggio C, Jilani K, Lang F: Aristolochic Acid Induced Suicidal Erythrocyte Death. Kidney Blood Press Res 2014;39:408-419.
34.
Officioso A, Alzoubi K, Manna C, Lang F: Clofazimine Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:331-341.
35.
Oswald G, Alzoubi K, Abed M, Lang F: Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014;114:311-317.
36.
Peter T, Bissinger R, Enkel S, Alzoubi K, Oswald G, Lang F: Programmed erythrocyte death following in vitro Treosulfan treatment. Cell Physiol Biochem 2015;35:1372-1380.
37.
Stockinger K, Bissinger R, Bouguerra G, Abbes S, Lang F: Enhanced Eryptosis Following Exposure to Carnosic Acid. Cell Physiol Biochem 2015;37:1779-1791.
38.
Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA: Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014;34:1075-1089.
39.
Waibel S, Bissinger R, Bouguerra G, Abbes S, Lang F: Saquinavir Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:1973-1982.
40.
Zierle J, Bissinger R, Egler J, Lang F: Lapatinib Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2275-2287.
41.
Bissinger R, Bouguerra G, Al Mamun Bhuyan A, Waibel S, Abbes S, Lang F: Efavirenz Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2496-2507.
42.
Bissinger R, Waibel S, Bouguerra G, Al Mamun Bhuyan A, Abbes S, Lang F: Enhanced Eryptosis Following Exposure to Lopinavir. Cell Physiol Biochem 2015;37:2486-2495.
43.
Briglia M, Calabro S, Signoretto E, Alzoubi K, Laufer S, Faggio C, Lang F: Fucoxanthin Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2464-2475.
44.
Briglia M, Fazio A, Faggio C, Lang F: Triggering of Suicidal Erythrocyte Death by Zosuquidar. Cell Physiol Biochem 2015;37:2355-2365.
45.
Fazio A, Briglia M, Faggio C, Alzoubi K, Lang F: Oxaliplatin Induced Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2015;37:2393-2404.
46.
Macczak A, Cyrkler M, Bukowska B, Michalowicz J: Eryptosis-inducing activity of bisphenol A and its analogs in human red blood cells (in vitro study). J Hazard Mater 2016;307:328-335.
47.
Officioso A, Alzoubi K, Lang F, Manna C: Hydroxytyrosol inhibits phosphatidylserine exposure and suicidal death induced by mercury in human erythrocytes: Possible involvement of the glutathione pathway. Food Chem Toxicol 2016;89:47-53.
48.
Officioso A, Manna C, Alzoubi K, Lang F: Bromfenvinphos induced suicidal death of human erythrocytes. Pestic Biochem Physiol 2016;126:58-63.
49.
Qadri SM, Donkor DA, Bhakta V, Eltringham-Smith LJ, Dwivedi DJ, Moore JC, Pepler L, Ivetic N, Nazi I, Fox-Robichaud AE, Liaw PC, Sheffield WP: Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin. J Cell Mol Med 2016;10.1111/jcmm.12778
50.
Zierle J, Bissinger R, Bouguerra G, Abbes S, Lang F: Triggering of Suicidal Erythrocyte Death by Regorafenib. Cell Physiol Biochem 2016;38:160-172.
51.
Pagano M, Faggio C: The use of erythrocyte fragility to assess xenobiotic cytotoxicity. Cell Biochem Funct 2015;33:351-355.
52.
Harrison HE, Bunting H, Ordway NK, Albrink WS: The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947;86:339-356.
53.
Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012;302:C644-C651.
54.
Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
55.
Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
56.
Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life 2005;62:971-988.
57.
Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
58.
Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
59.
Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
60.
Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996;88:1873-1880.
61.
Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013;37:567-578.
62.
Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F: Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013;38:42-51.
63.
Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F: Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014;92:871-879.
64.
Ahmed MS, Langer H, Abed M, Voelkl J, Lang F: The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013;37:158-167.
65.
Polak-Jonkisz D, Purzyc L: Ca2+ influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012;34:209-210; author reply 210.
66.
Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
67.
Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006;84:378-388.
68.
Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232.
69.
Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA: Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015;61:275-284.
70.
Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007;85:273-281.
71.
Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
72.
Kasiotis KM, Pratsinis H, Kletsas D, Haroutounian SA: Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties. Food Chem Toxicol 2013;61:112-120.
73.
Liu B, Zhou Z, Zhou W, Liu J, Zhang Q, Xia J, Liu J, Chen N, Li M, Zhu R: Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways. Mol Med Rep 2014;10:1697-1702.
74.
Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S, Lee KW, Suh JY, Lee HJ, Tsang BK: Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem 2013;288:23740-23750.
75.
Qadri SM, Foller M, Lang F: Inhibition of suicidal erythrocyte death by resveratrol. Life Sci 2009;85:33-38.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.